Related Experiment Video

Updated: May 17, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Activin receptor antagonists for cancer-related anemia and bone disease

Scott Z Fields1, Shiroo Parshad, Madhurima Anne

  • 1Monter Cancer Center, Hofstra North Shore-LIJ School of Medicine, Lake Success, NY, USA.

Expert Opinion on Investigational Drugs
|November 7, 2012
PubMed
Abstract

Insights

Activin receptor antagonists, like sotatercept, show promise for treating cancer-related anemia and bone diseases. These novel therapies offer potential benefits in multiple myeloma and other malignancies.

Area of Science:

  • Oncology
  • Hematology
  • Bone Biology

Background:

  • Dysregulated activin receptor signaling contributes to cancer-related anemia and bone diseases, including multiple myeloma.
  • Malignancies such as multiple myeloma and solid tumors are associated with significant anemia and bone complications.

Purpose of the Study:

  • To review the role of activin receptor pathways in cancer-related anemia, myeloma-associated osteolysis, and metastatic bone disease.
  • To evaluate the therapeutic potential of activin receptor antagonists in clinical development for these conditions.

Main Methods:

  • Review of preclinical and clinical evidence for activin receptor antagonists.
  • Analysis of signaling pathways involved in cancer-related anemia and bone disease.
  • Examination of sotatercept's mechanism of action and clinical data.

Main Results:

  • Sotatercept, a novel activin receptor type IIA (ActRIIA) ligand trap, increased red blood cells (RBC) in preclinical models and clinical studies.
  • Preclinical studies showed sotatercept inhibited tumor growth, metastasis, and promoted bone anabolism in multiple myeloma models.
  • Small-molecule inhibitors of TGF-β receptor type I (ALK5), such as LY-2157299, demonstrated preclinical antitumor activity.

Conclusions:

  • Activin receptor antagonists, including sotatercept, represent a promising therapeutic strategy for cancer-related anemia, particularly those with ineffective erythropoiesis.
  • Sotatercept's anabolic bone activity and potential antitumor effects position it as a candidate for multiple myeloma and malignant bone diseases.
  • Activin receptor antagonists are identified as attractive therapeutic candidates for a range of diseases due to their multifaceted preclinical and clinical effects.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...